Answers are grounded in this paper and cite their sources.
Clinical trial comparing rituximab and steroids for remission in nephrotic syndrome, indicating safety benefits of RTX.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: